DGK 2021

Published: 11 October 2021

  • Views:

    Views Icon 1156
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

DGK 2021

 

This page contains 5 clips of presentations from DGK 2021.

This content is sponsored by ZOLL

More from this programme

Part 1

DGK 2021, C.W. Israel: Current and Future Strategies for SCD Risk Stratification

C.W: Israel demonstrates the still existing high risk of SCD for patients after acute cardiac events and presents the challenges to stratify this risk.

Part 2

DGK 2021, J. Ehrlich: Update on the Clinical Evidence of the Wearable Cardioverter Defibrillator in the International Context

J. Ehrlich provides an update on the clinical evidence on the WCD incl. new European data from France, Switzerland and Austria and further highlights the arrhythmic and total mortality benefits for patients that wear the WCD based on the VEST per-protocol analysis.

Part 3

DGK 2021, A. Hain: Contemporary Management of Patients With Heart Failure

A. Hain presents the 2021 ESC Heart Failure guidelines highlighting the update on the first line drug therapy and presents how the WCD can support the phase of uptitration to achieve optimal medical therapy e.g. WCD heart rate data.

Part 4

DGK 2021, S. Göbel: Possible Applications of the Wearable Cardioverter Defibrillator in Clinical Practice

S. Göbel presents the indications for the WCD according to the German “Hilfsmittelverzeichnis” and shows the applications of the WCD according to American guidelines and an EHRA positing paper. Furthermore he presents the practical applications of the WCD showing several patient cases from the University Medical Centre in Mainz, Germany.

Part 5

DGK 2021, C.A. Perings: Discussion and Summary

C.A. Perings concludes by highlighting the broad range of indications under which patients at risk for SCD can be protected with the WCD in Germany.

Faculty Biographies

Sebastian Göbel

View full profile